Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?
Syndax Pharmaceuticals Ownership Summary
Syndax Pharmaceuticals is owned by 117.90% institutional investors, 1.30% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.57% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.
SNDX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Syndax Pharmaceuticals | 117.90% | 1.30% | -19.19% |
| Sector | Healthcare Stocks | 279.18% | 10.62% | -189.80% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 9.03M | 10.57% | $119.43M |
| Kynam capital management, lp | 8.52M | 9.97% | $112.63M |
| Blackrock | 7.91M | 9.28% | $162.33M |
| Goldman sachs group | 5.95M | 6.97% | $78.67M |
| Vanguard group | 4.88M | 5.71% | $64.54M |
| Wellington management group llp | 4.23M | 4.96% | $55.98M |
| State street | 3.62M | 4.25% | $74.37M |
| Stempoint capital lp | 2.87M | 3.36% | $37.98M |
| Soleus capital management | 2.49M | 2.92% | $32.94M |
| Assenagon asset management | 2.06M | 2.42% | $27.29M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Stempoint capital lp | 2.87M | 9.48% | $37.98M |
| Kynam capital management, lp | 8.52M | 6.66% | $112.63M |
| Saturn v capital management | 988.53K | 5.12% | $13.07M |
| Aisling capital management lp | 1.02M | 4.81% | $13.55M |
| Lion point capital, lp | 55.00K | 3.81% | $727.10K |
| Kingdon capital management | 2.00M | 3.77% | $26.44M |
| Silverarc capital management | 1.23M | 3.56% | $16.27M |
| Prosight management, lp | 551.54K | 3.38% | $11.32M |
| Sphera funds management | 1.38M | 3.30% | $18.26M |
| Exome asset management | 318.90K | 3.17% | $4.22M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Goldman sachs group | 5.95M | 0.01% | 4.34M |
| Kynam capital management, lp | 8.52M | 6.66% | 2.68M |
| Assenagon asset management | 2.06M | 0.04% | 1.60M |
| Soleus capital management | 2.49M | 2.07% | 1.40M |
| Stempoint capital lp | 2.87M | 9.48% | 1.14M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Eversept partners, lp | 343.40K | 0.40% | -3.76M |
| Avoro capital advisors | - | - | -2.27M |
| Orbimed advisors | - | - | -1.93M |
| Bvf inc/il | - | - | -1.88M |
| State street | 3.62M | 0.00% | -1.20M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Octagon capital advisors lp | 904.00K | 1.97% | 904.00K | $11.95M |
| Prosight management, lp | 551.54K | 3.38% | 551.54K | $11.32M |
| Cubist systematic strategies | 358.07K | 0.03% | 358.07K | $4.73M |
| Exome asset management | 318.90K | 3.17% | 318.90K | $4.22M |
| Man group | 121.54K | 0.00% | 121.54K | $1.61M |
Sold Out
| Holder | Change |
|---|---|
| Tfc financial management | -1.00 |
| Nelson, van denburg & campbell wealth management group | -13.00 |
| Srs capital advisors | -14.00 |
| Riggs asset managment | -26.00 |
| Innealta capital | -48.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 233 | 2.19% | 100,944,775 | 2.97% | 117 | 0.90% | 119 | -7.03% | 65 | 10.17% |
| Dec 31, 2024 | 216 | -5.68% | 91,955,124 | 3.35% | 107 | 0.99% | 119 | -4.03% | 58 | -1.69% |
| Sep 30, 2024 | 225 | 11.39% | 88,858,869 | 1.79% | 104 | 0.99% | 121 | 10.00% | 59 | -3.28% |
| Jun 30, 2024 | 200 | 2.56% | 87,296,966 | -3.26% | 102 | 0.66% | 109 | -3.54% | 60 | 11.11% |
| Mar 31, 2024 | 195 | 4.28% | 90,236,973 | 1.79% | 124 | 0.77% | 113 | -4.24% | 54 | 31.71% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Health Care Inv | 2.99M | 3.50% | - |
| Vanguard Total Stock Mkt Idx Inv | 2.62M | 3.04% | 66.70K |
| Vanguard US Total Market Shares ETF | 2.60M | 3.01% | 4.69K |
| iShares Russell 2000 ETF | 2.09M | 2.43% | 1.03K |
| SPDR® S&P Biotech ETF | 1.94M | 2.25% | 2.50K |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.33M | 1.54% | 2.02K |
| Eventide Healthcare & Life Sciences I | 1.18M | 1.37% | 391.07K |
| Fidelity Small Cap Index | 818.99K | 0.95% | 9.77K |
| Franklin Biotechnology Discv A(acc)USD | 814.51K | 0.95% | - |
| iShares Russell 2000 Growth ETF | 719.08K | 0.84% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 19, 2025 | Goldan Keith A. | Chief Financial Officer | Buy | - |
| May 16, 2025 | Botwood Nicholas A.J. | Head of R&D, CMO | Buy | $105.83K |
| May 19, 2025 | Huber Martin H. Jr. | - | Buy | $44.95K |
| May 19, 2025 | Katkin Keith | - | Buy | $91.12K |
| Mar 04, 2025 | Metzger Michael A | Chief Executive Officer | Sell | $117.56K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | 4 | - |
| 2025 Q1 | - | 4 |
| 2024 Q2 | 1 | - |
| 2024 Q1 | - | - |
| 2023 Q3 | - | 5 |
SNDX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools